File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

TitleHigh expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
Authors
KeywordsChemoradiotherapy
Esophageal squamous cell carcinoma
EZH2
Immunohistochemistry
Prognosis
Issue Date2010
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
Citation
International Journal Of Cancer, 2010, v. 127 n. 1, p. 137-147 How to Cite?
AbstractThe enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported to be associated with biological malignancy in several cancers. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in esophageal squamous cell carcinoma (ESCC) are unclear. In this study, the methods of immunohistochemistry and fluorescence in-situ hybridization were used to examine protein expression and amplification of EZH2 in 98 pretreatment biopsy specimens of ESCC who received definitive chemoradiotherapy (CRT). High expression of EZH2 and amplification of EZH2 was found in 54.1% and 12.0% of ESCCs, respectively. High EZH2 expression was significantly correlated with increased cell proliferation (p = 0.009), high histopathological grade (p = 0.002), regional (p = 0.025) and distant lymph node metastasis (p < 0.001) and lack of clinical complete response to CRT (p 5 0.028). Univariate analysis revealed that high expression of EZH2 was associated with poor metastasis-free survival (MFS) (p = 0.003), poor progression-free survival (PFS) (p = 0.001) and poor disease-specific survival (DSS) (p < 0.001). In multivariate analysis, high expression of EZH2, together with lack of clinical complete response, were evaluated as significant independent prognostic factors of MFS, PFS and DSS for patients with ESCC. These findings suggest that high expression of EZH2 correlates with tumor aggressiveness and adverse patient outcome in ESCC treated with definitive CRT. Evaluation of EZH2 expressions might be useful for predicting tumor response to CRT and prognosis for patients with ESCC. © 2009 UICC.
Persistent Identifierhttp://hdl.handle.net/10722/124523
ISSN
2014 Impact Factor: 5.085
ISI Accession Number ID
Funding AgencyGrant Number
Major State Basic Research Program of China2006CB910104
863 Project of China2007AA021901
Funding Information:

Grant sponsor: Major State Basic Research Program of China; Grant number: 2006CB910104; Grant sponsor: the 863 Project of China; Grant number: 2007AA021901

References

 

DC FieldValueLanguage
dc.contributor.authorHe, LRen_HK
dc.contributor.authorLiu, MZen_HK
dc.contributor.authorLi, BKen_HK
dc.contributor.authorJia, WHen_HK
dc.contributor.authorZhang, Yen_HK
dc.contributor.authorLiao, YJen_HK
dc.contributor.authorChen, YCen_HK
dc.contributor.authorZhang, LJen_HK
dc.contributor.authorGuan, XYen_HK
dc.contributor.authorZeng, YXen_HK
dc.contributor.authorKung, HFen_HK
dc.contributor.authorXie, Den_HK
dc.date.accessioned2010-10-31T10:39:14Z-
dc.date.available2010-10-31T10:39:14Z-
dc.date.issued2010en_HK
dc.identifier.citationInternational Journal Of Cancer, 2010, v. 127 n. 1, p. 137-147en_HK
dc.identifier.issn0020-7136en_HK
dc.identifier.urihttp://hdl.handle.net/10722/124523-
dc.description.abstractThe enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported to be associated with biological malignancy in several cancers. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in esophageal squamous cell carcinoma (ESCC) are unclear. In this study, the methods of immunohistochemistry and fluorescence in-situ hybridization were used to examine protein expression and amplification of EZH2 in 98 pretreatment biopsy specimens of ESCC who received definitive chemoradiotherapy (CRT). High expression of EZH2 and amplification of EZH2 was found in 54.1% and 12.0% of ESCCs, respectively. High EZH2 expression was significantly correlated with increased cell proliferation (p = 0.009), high histopathological grade (p = 0.002), regional (p = 0.025) and distant lymph node metastasis (p < 0.001) and lack of clinical complete response to CRT (p 5 0.028). Univariate analysis revealed that high expression of EZH2 was associated with poor metastasis-free survival (MFS) (p = 0.003), poor progression-free survival (PFS) (p = 0.001) and poor disease-specific survival (DSS) (p < 0.001). In multivariate analysis, high expression of EZH2, together with lack of clinical complete response, were evaluated as significant independent prognostic factors of MFS, PFS and DSS for patients with ESCC. These findings suggest that high expression of EZH2 correlates with tumor aggressiveness and adverse patient outcome in ESCC treated with definitive CRT. Evaluation of EZH2 expressions might be useful for predicting tumor response to CRT and prognosis for patients with ESCC. © 2009 UICC.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/homeen_HK
dc.relation.ispartofInternational Journal of Canceren_HK
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc..-
dc.rightsThis is a preprint of an article published in International Journal of Cancer, 2010, v. 127 n. 1, p. 138-147-
dc.subjectChemoradiotherapyen_HK
dc.subjectEsophageal squamous cell carcinomaen_HK
dc.subjectEZH2en_HK
dc.subjectImmunohistochemistryen_HK
dc.subjectPrognosisen_HK
dc.subject.meshEsophageal squamous cell carcinoma-
dc.subject.meshEZH2-
dc.subject.meshChemoradiotherapy-
dc.subject.meshPrognosis-
dc.subject.meshImmunohistochemistry-
dc.titleHigh expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0020-7136&volume=127&issue=1&spage=138&epage=147&date=2010&atitle=High+expression+of+EZH2+is+associated+with+tumor+aggressiveness+and+poor+prognosis+in+patients+with+esophageal+squamous+cell+carcinoma+treated+with+definitive+chemoradiotherapyen_HK
dc.identifier.emailGuan, XY:xyguan@hkucc.hku.hken_HK
dc.identifier.authorityGuan, XY=rp00454en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ijc.25031en_HK
dc.identifier.pmid19904743-
dc.identifier.scopuseid_2-s2.0-77953444201en_HK
dc.identifier.hkuros175308en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77953444201&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume127en_HK
dc.identifier.issue1en_HK
dc.identifier.spage137en_HK
dc.identifier.epage147en_HK
dc.identifier.isiWOS:000278148800015-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHe, LR=35069492500en_HK
dc.identifier.scopusauthoridLiu, MZ=35285929300en_HK
dc.identifier.scopusauthoridLi, BK=26663761000en_HK
dc.identifier.scopusauthoridJia, WH=26422262500en_HK
dc.identifier.scopusauthoridZhang, Y=35188429500en_HK
dc.identifier.scopusauthoridLiao, YJ=36114448500en_HK
dc.identifier.scopusauthoridChen, YC=24075600300en_HK
dc.identifier.scopusauthoridZhang, LJ=35772164700en_HK
dc.identifier.scopusauthoridGuan, XY=7201463221en_HK
dc.identifier.scopusauthoridZeng, YX=7402981579en_HK
dc.identifier.scopusauthoridKung, HF=7402514190en_HK
dc.identifier.scopusauthoridXie, D=35070710200en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats